<DOC>
	<DOCNO>NCT01620749</DOCNO>
	<brief_summary>The purpose study investigate safety potential effectiveness image compound 18F MEL050 find site melanoma .</brief_summary>
	<brief_title>Of 18F MEL050 Using PET/CT Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Written inform consent obtain prior protocolspecific procedure Male female patient histologically confirm melanoma At least one site metastatic disease , demonstrate prestudy 18F FDG PET/CT scan perform part routine clinical care Age &gt; /= 18 year Life expectancy &gt; /=3 month ECOG performance score 02 Pregnant breastfeeding female Systemic antimelanoma therapy within 2 week prior prestudy 18F FDG PET/CT scan 18F MEL050 PET/CT scan Patients whose clinical care may compromise delay result performance 18F MEL050 PET/CT scan Patients whose metastatic lesion Central Nervous System Patients urinary incontinence patient comfortably hold urine 90 minute Any serious medical condition investigator feel may interfere procedure evaluation study Patients unwilling unable comply protocol patient history non compliance inability grant inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>melanoma metastatic diagnosis</keyword>
</DOC>